Abstract
Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B®; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).
| Original language | English |
|---|---|
| Pages (from-to) | 726-730 |
| Number of pages | 5 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 11 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 1992 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Black children
- Hepatitis B vaccine
- Immunogenicity
Fingerprint
Dive into the research topics of 'Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver